---
layout: default
title: Verapamil
parent: Model Prediction Only (L5)
nav_order: 964
evidence_level: L5
indication_count: 7
---

# Verapamil
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **7** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Verapamil: From Cardiovascular Calcium Channel Blocker Use to Obsolete Bundle Branch Block

## One-Sentence Summary

Verapamil is a calcium channel blocker that is marketed in Canada and has established cardiovascular and antihypertensive use.
The TxGNN model predicts it may be effective for **obsolete bundle branch block**, but **0 clinical trials** and **0 publications** support this prediction.
The prediction is model output only, and the "obsolete" label on the disease term suggests an ontology artifact rather than a real clinical target.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not listed in the Canadian license records (drug class: L-type calcium channel blocker) |
| Predicted New Indication | Obsolete bundle branch block |
| TxGNN Prediction Score | 99.62% |
| Evidence Level | L5 |
| Canada Market Status | ✓ Marketed |
| Number of DINs | 5 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in the source record. Verapamil blocks L-type calcium channels and slows atrioventricular (AV) nodal conduction. It also has vasodilating, antihypertensive effects.

The link to bundle branch block is weak. Bundle branch block is a conduction-system disorder, and slowing conduction is not an obvious treatment for it. Verapamil is generally used with caution in patients with conduction disease. The disease term is also labelled "obsolete," which points to a knowledge-graph artifact rather than a genuine therapeutic target. The very high score (99.62%) is not backed by any trial or publication.

Other top predictions for this drug are mostly hypertension-related (malignant hypertensive renal disease, malignant renovascular hypertension). These are plausible at the drug-class level, but they are also model-only (L5) and have no direct verapamil evidence.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Canada Market Information

| DIN | Product Name |
|---------|------|
| 782483 | AA-VERAP |
| 782491 | AA-VERAP |
| 2166739 | VERAPAMIL HYDROCHLORIDE INJECTION USP |
| 1907123 | ISOPTIN SR |
| 2210347 | MYLAN-VERAPAMIL SR |

---

## Safety Considerations

- **Drug Interactions**: No interaction records were found in the queried source.
- **Conduction disease**: Verapamil slows AV nodal conduction and is generally used with caution in conduction disease. This is directly relevant to the proposed indication.

Please refer to the package insert for full warnings and contraindications.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The prediction rests on the model score alone, with no trials or literature. The mechanism is unfavorable, since conduction slowing is not a plausible treatment for bundle branch block. The disease term is obsolete and likely an ontology artifact.

**To proceed, the following is needed:**
- Health Canada product monograph (warnings, contraindications, approved indications), which is a blocking gap for safety screening
- Mechanism of action data from DrugBank
- Confirmation of whether the "obsolete bundle branch block" term maps to any current clinical entity
- Consideration of the hypertension-related predictions (ranks 2–3) as better-grounded candidates, which would still need literature and trial review
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

